Differential diagnosis of acute miliary pulmonary tuberculosis from widespread-metastatic cancer for postoperative lung cancer patients: two cases

Abstract Background Little is known about patterns of and factors associated with treatment for de novo metastatic cancer patients who die soon after diagnosis. In this study, we examine treatment patterns for patients newly diagnosed with metastatic lung, colorectal, breast, or pancreatic cancer who died within 1 month of diagnosis. Methods We identified 100 848 adult patients in the National Cancer Database with de novo metastatic lung, colorectal, breast, and pancreatic cancer, diagnosed between 2004 and 2014 and who died within 1 month. We performed descriptive and multivariable logistic regression analyses to examine receipt of surgery, chemotherapy, radiation, and hormonal therapy by cancer type, adjusting for sociodemographic and clinical variables. Results Treatment substantially varied by cancer type, over time, age, insurance, and facility type. Surgery ranged from 0.4% in pancreatic to 28.3% in colorectal cancer (CRC) patients, chemotherapy from 5.8% among CRC to 11% in lung and breast cancer patients, and radiotherapy from 1.3% in pancreatic to 18.7% in lung cancer patients. Use of some treatments (eg, surgery for CRC and breast cancer) progressively declined between 2004 and 2014. Compared with lung cancer patients treated at National Cancer Institute-designated cancer centers, those treated at community cancer centers had 48% lower odds of radiation. Conclusions Treatment of patients diagnosed with imminently fatal de novo metastatic cancer varied markedly by cancer type and patient/facility characteristics. These variations warrant more research to better identify patients with imminently fatal de novo metastatic cancer who may not benefit from aggressive and expensive therapies.

Download Full-text

Shortened Survival of Lung Cancer Patients Initially Presenting with Pulmonary Tuberculosis

Japanese Journal of Clinical Oncology ◽

10.1093/oxfordjournals.jjco.a023240 ◽

1996 ◽

Vol 26 (5) ◽

pp. 322-327 ◽

Cited By ~ 16

Author(s):

Y.-M. Chen ◽

J.-Y. Chao ◽

C.-M. Tsai ◽

P.-Y. Lee ◽

R.-P. Perng

Keyword(s):

Lung Cancer ◽

Pulmonary Tuberculosis ◽

Cancer Patients ◽

Lung Cancer Patients

Download Full-text

Fucosylation of serum glycoproteins in lung cancer patients

Clinical Chemistry and Laboratory Medicine (CCLM) ◽

10.1515/cclm.2005.066 ◽

2005 ◽

Vol 43 (4) ◽

Cited By ~ 30

Author(s):

Barbara Kossowska ◽

Mirosława Ferens-Sieczkowska ◽

Roman Gancarz ◽

Ewa Passowicz-Muszyńska ◽

Renata Jankowska

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Cells ◽

Cancer Patients ◽

Metastatic Cancer ◽

Small Cell ◽

Sialyl Lewis X ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Sialyl Lewis

AbstractIncreased expression of sialyl Lewis X or A antigens on metastatic cancer cells leads to their selectin-mediated extravasation. Profound fucosylation of the serum microenvironment may be a factor that interrupts adhesion and influences the formation of metastases. In this study we quantitatively analyzed fucosylation of serum glycoproteins in small-cell and non-small-cell lung cancer patients. Fucosylation of four chosen glycoprotein bands was measured as the reactivity with

Download Full-text

Use quantitative parameters in spectral computed tomography for the differential diagnosis of metastatic mediastinal lymph nodes in lung cancer patients

Journal of Thoracic Disease ◽

10.21037/jtd-21-385 ◽

2021 ◽

Vol 0 (0) ◽

pp. 0-0

Author(s):

Suidan Huang ◽

Hongjia Meng ◽

Renli Cen ◽

Zhiwen Ni ◽

Xiaoling Li ◽

...

Keyword(s):

Computed Tomography ◽

Lung Cancer ◽

Differential Diagnosis ◽

Lymph Nodes ◽

Cancer Patients ◽

Mediastinal Lymph Nodes ◽

Lung Cancer Patients ◽

Quantitative Parameters ◽

Spectral Computed Tomography

Download Full-text

The Effects of Serum hs-CRP on the Incidence of Lung Cancer in Male Patients with Pulmonary Tuberculosis

Iranian Journal of Public Health ◽

10.18502/ijph.v48i7.2949 ◽

2020 ◽

Author(s):

Youhua JIANG ◽

Kewei NI ◽

Meiyu FANG ◽

Junling LIU

Keyword(s):

Lung Cancer ◽

Pulmonary Tuberculosis ◽

Cancer Patients ◽

Serum Levels ◽

Incidence Rates ◽

Lung Cancer Patients ◽

Group A ◽

Male Patients ◽

Hs Crp ◽

Group B

Background: This study intended to investigate the effects of serum high-sensitivity C-reactive protein (hs-CRP) on the incidence of lung cancer in male patients with pulmonary tuberculosis. Methods: A total of 1091 male patients with pulmonary tuberculosis in Zhejiang Cancer Hospital, Hangzhou, China from Jan 2009 to Jan 2012 were selected as the research objects. All patients were followed up from the beginning of hospitalization. According to serum hs-CRP level, patients were divided into two groups: group A (hs-CRP < 1 mg/L) and group B (hs-CRP > 3 mg/L). The relationship between baseline hs-CRP and the risk of lung cancer in patients with pulmonary tuberculosis was analyzed by multivariate Cox proportional risk regression model, and the serum levels of hs-CRP between lung cancer patients in all groups and other non-lung cancer patients were compared. Results: There were differences in age, drinking, smoking, diabetes history, body mass index (BMI), thyroglobulin (TG), history of hypertension and hyperglycemia among the three groups (P=0.036, 0.018, 0.040, 0.029, 0.006, 0.034, 0.020, 0.010). The serum levels of hs-CRP in patients with squamous carcinoma, adenocarcinoma and small cell carcinoma were significantly higher than those in non-lung cancer patients (P=0.022, 0.043, 0.011). The incidence rates of lung cancer in patients in group B and C were 1.37 and 1.69 times higher than that in group A, respectively. Conclusion: The increased serum level of hs-CRP will increase the incidence rate of lung cancer in male patients with pulmonary tuberculosis.

Download Full-text

PS01.18: The Characteristics of Active Pulmonary Tuberculosis in Lung Cancer Patients

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2016.09.053 ◽

2016 ◽

Vol 11 (11) ◽

pp. S279-S280

Author(s):

Suk Joong Yong ◽

Myoungkyu Lee ◽

Won-Yeon Lee ◽

Sang-Ha Kim ◽

Seok Jeong Lee

Keyword(s):

Lung Cancer ◽

Pulmonary Tuberculosis ◽

Cancer Patients ◽

Active Pulmonary Tuberculosis ◽

Lung Cancer Patients

Download Full-text

Clinical characteristics and survival of patients concurrently diagnosed with lung cancer and active pulmonary tuberculosis

10.21203/rs.3.rs-279237/v1 ◽

2021 ◽

Author(s):

Hwa Young Lee ◽

Jung Won Heo ◽

Hye Seon Kang ◽

Ji Young Kang ◽

Jin Woo Kim ◽

...

Keyword(s):

Lung Cancer ◽

Pulmonary Tuberculosis ◽

Cancer Patients ◽

Clinical Characteristics ◽

Positive Culture ◽

The Body ◽

Pulmonary Tb ◽

Active Pulmonary Tuberculosis ◽

Lung Cancer Patients ◽

Clinical Stages

Abstract Background Active pulmonary tuberculosis (TB) occasionally coexists with lung cancer. However, the clinical and radiologic characteristics of this cooccurrence have not been fully evaluated. Methods Patients diagnosed with lung cancer and active pulmonary TB from January 2009 to December 2017 in four hospitals of the Catholic University of Korea were retrospectively reviewed. The clinical characteristics, including the TB diagnosis methods, lung cancer pathology, staging, initial radiographic features, and survival were analyzed and compared to 575 lung cancer patients without active pulmonary TB from the same hospitals. Results Forty-eight (0.48%) of the 9,936 lung cancer patients had active pulmonary TB confirmed by positive culture results or polymerase chain reaction analysis for M. tuberculosis at the time of the initial cancer diagnosis. The majority of the patients (95.9%) had non-small cell lung cancer and 56.2% of the lung cancers were located in the both upper lobes. In the initial computed tomography, the most frequent findings were a mass-like lesion (79.2%) and separate nodules (75%). When compared to lung cancer patients without TB, the body mass index (BMI) was lower (21.4 vs. 23.1, P = 0.001) in patients with TB. Moreover, the lung cancer patients with TB had advanced clinical stages compared to patients without TB; T3-4 (70.9% vs. 50.6%, P = 0.002), N2-3 (85.2% vs. 55.6%, P < 0.001); M1 (65.9% vs. 44.5%, P = 0.007). Patients' age, histology, location, and the presence of epidermal growth factor receptor mutations were not statistically different between the two groups. Interestingly, lung cancer with TB was associated with lower mortality (hazard ratio = 0.35, 95% CI: 0.2 1– 0.60). Conclusions Rarely diagnosed concurrent active tuberculosis in lung cancer patients was associated with lower BMI and advanced clinical stages. Active investigation of and treatment for active pulmonary TB in lung cancer patients could improve patient outcomes.

Download Full-text

Coexistence of lung squamous cell carcinoma and pulmonary tuberculosis within a single lesion: a case report

10.21203/rs.3.rs-17664/v1 ◽

2020 ◽

Author(s):

Guoliang Xiao ◽

Shengjie Chen

Keyword(s):

Lung Cancer ◽

Squamous Cell Carcinoma ◽

Pulmonary Tuberculosis ◽

Cell Carcinoma ◽

Cancer Patients ◽

Squamous Cell ◽

Left Lung ◽

Lung Squamous Cell Carcinoma ◽

Active Pulmonary Tuberculosis ◽

Lung Cancer Patients

Abstract Background: Tuberculosis and lung cancer are common high-mortality lung diseases, but it is rare that lung cancer and tuberculosis exist in the same lesion. In addition, lung cancer with pulmonary tuberculosis is similar in morphology to lung cancer without tuberculosis. For these reasons, lung cancer patients with tuberculosis are often misdiagnosed and mistreated, so these patients have a poorer prognosis than lung cancer patients without tuberculosis. Therefore, a full understanding of such cases can help early diagnosis, so that appropriate treatments can be performed timely. Case presentations: A 52-year-old male. The physical examination revealed a cavity-like nodule in the upper left lung and the first diagnosis was tuberculosis. There was no significant change in lung nodules after anti-tuberculosis treatment. So the patient was admitted to the hospital for surgical treatment of lung cancer. Postoperative pathological showed that the lesion was lung squamous cell carcinoma with tuberculosis.Conclusion: the survival rate of patients with active pulmonary tuberculosis and lung cancer is lower than those with lung cancer or tuberculosis alone. Which is mainly due to incomplete diagnosis. if we find hollow shadows in the lungs on CT, we should think about the possibility of coexistence of lung cancer and tuberculosis, and then the appropriate treatment and management strategies should be developed.

Download Full-text

The Delay in The Diagnosis of Lung Cancer Due to Misdiagnosis as Pulmonary Tuberculosis

Jurnal Respirologi Indonesia ◽

10.36497/jri.v37i4.83 ◽

2017 ◽

Vol 37 (4) ◽

pp. 288-292

Author(s):

Jatu Aviani ◽

Satria Maulana EH ◽

Ita Haryatie ◽

Farih Raharjo ◽

Yusup Subagio Sutanto ◽

...

Keyword(s):

Lung Cancer ◽

Pulmonary Tuberculosis ◽

Cell Carcinoma ◽

Cancer Patients ◽

Small Cell Lung Carcinoma ◽

Delayed Diagnosis ◽

Cell Lung Carcinoma ◽

Pulmonary Tb ◽

Lung Cancer Patients ◽

Diagnosis Of Lung Cancer

Background: Lung cancer and pulmonary tuberculosis (TB) are global health problem. Similarity of symptoms of both made misdiagnose of lung cancer as TB and treated with Anti Tuberculosis Treatment (ATT). Evaluation of ATT often inaccurate, causing late diagnosis of lung cancer. This study aimed is to determine the lung cancer percentage with delayed diagnosis due giving of ATT for >1 month. Methods: A prospective descriptive study was performed from January 2014-February 2016 in Dr. Moewardi Hospital, Surakarta taken from the patient's medical record. Results: As much 293 patients with lung cancer consisted of 188 males (64.4%) and 105 females (35.8%) with the average age was 57 years old. The types of the lung cancer were non-small cell lung carcinoma (NSCLC) consisted of adenocarcinoma 195 subjects (66.6%), squamous cell carcinoma 65 subjects (22.2%), large cell carcinoma 23 subjects (7.8%) and neuroendocrine carcinoma 4 subjects (1.4%). The stages of the NSCLC were stage I (0%), II (0%), IIIa (0%), IIIb (11.7%) and IV (88.3%). Among 293 lung cancer patients, 89 subjects (30.4%) were diagnosis as pulmonary TB. Two subjects (2.2%) of 89 subjects were truly pulmonary TB while the rest 87 subjects were not pulmonary TB and had ATT for average 12 weeks with the longest period was 16 weeks. The ATT duration >1 month was 76.4%. Conclusions: Percentage of lung cancer patients with ATT before being referred to dr. Moewardi hospital were 30.4% of 293 lung cancer patients while 68 subjects (76.4%) of whom had received ATT >1 month. (J Respir Indo. 2017; 37(4): 288-92)

Download Full-text